London, UK -- (MARKET WIRE) -- April 18, 2007 --
CIRCULAR POSTED TODAY TO SHAREHOLDERS
LONDON, UK, APRIL 18, 2007-- SkyePharma PLC (LSE: SKP; NASDAQ: SKYE) announces that a Circular containing details of a new long-term incentive plan (the "LTIP") will today be posted to shareholders.
The Circular includes a notice convening an Extraordinary General Meeting to be held at 11.00 a.m. on 4 May 2007 at the offices of Fasken Martineau Stringer Saul LLP, 4th Floor, 17 Hanover Square, London, W1S 1HU at which a resolution will be proposed to approve the LTIP.
For further information please contact:
SkyePharma PLC +44 207 491 1777
Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer
Peter Grant, Finance Director
Financial Dynamics +44 207 7831 3113
David Yates
Deborah Scott
The Trout Group + 1 617 583 1308
Seth Lewis
About SkyePharma PLC
Using its proprietary drug delivery technologies, SkyePharma develops new
formulations of known molecules to provide a clinical advantage and life-cycle extension. The Company has nine approved products in the areas of oral, inhalation and topical delivery that are marketed throughout the world by leading pharmaceutical companies. For more information, visit
www.skyepharma.com.
This information is provided by RNS
The company news service from the London Stock Exchange